Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NovaBridge Biosciences ( (NBP) ) just unveiled an update.
On January 6, 2026, NovaBridge Biosciences reported updated Phase 1b data showing that its Claudin 18.2 x 4‑1BB bispecific antibody givastomig, in combination with nivolumab and mFOLFOX6 chemotherapy, produced robust objective response rates of 77% at 8 mg/kg and 73% at 12 mg/kg in U.S. patients with HER2‑negative, first‑line metastatic gastric cancer, with responses seen across a broad range of PD‑L1 and CLDN18.2 expression levels and a median progression-free survival of 16.9 months at the 8 mg/kg dose as of a December 2, 2025 cutoff. The regimen’s safety profile was broadly comparable to current first-line standards of care, with manageable immune‑related gastritis that appeared to correlate with better outcomes, and the strength of these data has prompted NovaBridge to proceed with a global randomized Phase 2 trial in the first quarter of 2026, positioning givastomig as a potential best‑in‑class CLDN18.2‑directed therapy and reinforcing the company’s competitive stance in the fast‑growing gastric cancer market.
The most recent analyst rating on (NBP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page.
Spark’s Take on NBP Stock
According to Spark, TipRanks’ AI Analyst, NBP is a Neutral.
The score is primarily held down by poor financial performance—zero revenue, heavy losses, and continued cash burn—partly offset by low balance-sheet leverage. Technicals are mixed (below key short/intermediate averages but above the 200-day, with mostly neutral momentum), while valuation is constrained by loss-driven negative earnings and the absence of dividend support.
To see Spark’s full report on NBP stock, click here.
More about NovaBridge Biosciences
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology platform company focused on accelerating access to innovative medicines, with a particular emphasis on oncology. Its pipeline includes novel immunotherapy and targeted biologic candidates such as givastomig, a bispecific antibody directed at Claudin 18.2 and 4-1BB, aimed at treating HER2‑negative, first-line metastatic gastric cancer, a market the company estimates could reach about $12 billion by 2030.
Average Trading Volume: 980,903
Technical Sentiment Signal: Buy
Current Market Cap: $503.8M
See more data about NBP stock on TipRanks’ Stock Analysis page.